title: Antibody therapy of acute myelogenous leukemia.
abstract: Monoclonal antibodies (mAbs) have become an important modality for cancer therapy. A genetically engineered, humanized anti-CD33 antibody HuM195 has demonstrated activity against over relapsed acute myelogenous leukemia (AML) and against minimal residual disease in acute promyelocytic leukemia (APL). Radioimmunotherapy with beta (beta) particle-emitting isotopes has produced significant responses while minimizing radiation exposure to normal tissues in both nonmyeloablative and myeloablative regimens. Targeted alpha (alpha) particle therapy with 213Bi-labeled HuM195 offers the possibility of more selective tumor cell kill. Additionally, directed chemotherapy using an anti-CD33-calicheamicin conjugate (CMA-676) has produced remissions in patients with relapsed AML.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. jurcicj@mskcc.org
authors.forename: J G
authors.initials: JG
authors.lastname: Jurcic
mesh_terms: D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001729:Bismuth; D002986:Clinical Trials as Topic; D000079982:Gemtuzumab; D006801:Humans; D007116:Immunization, Passive; D018796:Immunoconjugates / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C101579:monoclonal antibody M195; D000079982:Gemtuzumab; D001729:Bismuth